At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02595 GENFLEET-B
Not Yet Opened 08-17 16:08:29
31.140
+0.300
+0.97%
High31.500Low29.540Vol990.04K
Open29.560D1 Closing30.840Amplitude6.36%
Mkt Cap11.96BTradable Cap10.96BTotal Shares384.00M
T/O30.53MT/O Rate0.28%Tradable Shares352.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious
Earnings Agent  ·  08-14
Earning Preview: GENFLEET-B revenue outlook hinges on milestone timing as institutions remain cautious
GENFLEET-B: Wellington Management Group LLP Acquires Shares, Long Position Rises to 7.0%
HK Disclosure  ·  08-17 17:12
GENFLEET-B: Wellington Management Group LLP Acquires Shares, Long Position Rises to 7.0%
GenFleet Therapeutics's Lung Cancer Drug Advances in Phase 3 Trial, First Patient Dosed
MT Newswires Live  ·  08-10
GenFleet Therapeutics's Lung Cancer Drug Advances in Phase 3 Trial, First Patient Dosed
GenFleet Rises Most in 4 Weeks on Progress of Gfh375 in Cancer Treatment
Reuters  ·  08-10
GenFleet Rises Most in 4 Weeks on Progress of Gfh375 in Cancer Treatment
GenFleet Doses First Patient in China Phase III Trial of KRAS G12D Inhibitor Gfh375 for NSCLC
Reuters  ·  08-10
GenFleet Doses First Patient in China Phase III Trial of KRAS G12D Inhibitor Gfh375 for NSCLC
Genfleet Therapeutics (Shanghai) - Gfh375 Advances to Registrational Phase Iii Study in China for Kras G12d-Mutant Nsclc
THOMSON REUTERS  ·  08-10
Genfleet Therapeutics (Shanghai) - Gfh375 Advances to Registrational Phase Iii Study in China for Kras G12d-Mutant Nsclc
GenFleet Therapeutics to Hold Board Meeting on Interim Results, Dividend Recommendation
Reuters  ·  08-06
GenFleet Therapeutics to Hold Board Meeting on Interim Results, Dividend Recommendation
GenFleet Therapeutics Sets 21 Aug 2026 Board Meeting to Approve H1 2026 Interim Results and Dividend Plan
Bulletin Express  ·  08-06
GenFleet Therapeutics Sets 21 Aug 2026 Board Meeting to Approve H1 2026 Interim Results and Dividend Plan
GenFleet Therapeutics Issues 13.60 Million New H Shares via HK$34.69 Placing, Lifts Total Issued Shares to 351.63 Million
Bulletin Express  ·  08-05
GenFleet Therapeutics Issues 13.60 Million New H Shares via HK$34.69 Placing, Lifts Total Issued Shares to 351.63 Million
Analysts Are Bullish on These NA Stocks: Guming Holdings Ltd. (HK:1364), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
TIPRANKS  ·  08-05
Analysts Are Bullish on These NA Stocks: Guming Holdings Ltd. (HK:1364), Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
Movement Alert｜GENFLEET-B Rises 5.45% in Regular Trading, Trading at HK$28.34
Market Focus  ·  07-31
Movement Alert｜GENFLEET-B Rises 5.45% in Regular Trading, Trading at HK$28.34
Movement Alert｜GENFLEET-B Falls 5.41% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Weigh on Shares
Market Focus  ·  07-30
Movement Alert｜GENFLEET-B Falls 5.41% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Weigh on Shares
Movement Alert｜GENFLEET-B Falls 5.49% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Pressure Pipeline
Market Focus  ·  07-29
Movement Alert｜GENFLEET-B Falls 5.49% in Regular Trading, Competitor RAS Inhibitor NDA Accepted by FDA Continues to Pressure Pipeline
Movement Alert｜GENFLEET-B Intraday Decline 5.12%, Competitor Revolution Medicines RAS Inhibitor NDA Accepted by FDA Sparks Competition Concerns
Market Focus  ·  07-28
Movement Alert｜GENFLEET-B Intraday Decline 5.12%, Competitor Revolution Medicines RAS Inhibitor NDA Accepted by FDA Sparks Competition Concerns
Wellington Management Group LLP Reduces Stake in GENFLEET-B by 8,400 Shares at HK$34.71 Per Share
Stock News  ·  07-22
Wellington Management Group LLP Reduces Stake in GENFLEET-B by 8,400 Shares at HK$34.71 Per Share
Movement Alert｜GenFleet Therapeutics-B Rises 5.76% in Regular Trading, Technical Recovery Following H-Share Placement Completion
Market Focus  ·  07-21
Movement Alert｜GenFleet Therapeutics-B Rises 5.76% in Regular Trading, Technical Recovery Following H-Share Placement Completion
Wellington Management Group LLP Boosts Stake in GENFLEET-B with Share Purchase
Stock News  ·  07-17
Wellington Management Group LLP Boosts Stake in GENFLEET-B with Share Purchase
GenFleet Therapeutics completes HK$466.90 million H-share placing and updates share capital structure
Bulletin Express  ·  07-17
GenFleet Therapeutics completes HK$466.90 million H-share placing and updates share capital structure
GENFLEET-B Successfully Places 13.6 Million Shares, Raising Approximately HK$467 Million Net
Stock News  ·  07-17
GENFLEET-B Successfully Places 13.6 Million Shares, Raising Approximately HK$467 Million Net
Genfleet Therapeutics Completes Placement of 13,600,000 New H Shares at HK$ 34.69 Each
Reuters  ·  07-17
Genfleet Therapeutics Completes Placement of 13,600,000 New H Shares at HK$ 34.69 Each
No data available

Introduction

Company Name.
GENFLEET-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The Company is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The Company mainly primarily operates in the domestic and international markets.
Issue price:
--